Abemaciclib
CDK 4/6 inhibitor
Verzenio
15 trials
Indicated for 1 condition
CDK 4/6 inhibitor
Verzenio
15 trials
Indicated for 1 condition
CYP17A1 inhibitor
Zytiga
89 trials
Indicated for 1 condition
Enzyme replacement
Replagal
10 trials
Indicated for 1 condition
Anti-CD52 antibody
Lemtrada
58 trials
Indicated for 2 conditions
Immunosupressant
Litak, Mavenclad, Leustatin
43 trials
Indicated for 2 conditions
MEK inhibitor
Cotellic
29 trials
Indicated for 1 condition
Anti-CD38 antibody
Darzalex
79 trials
Indicated for 1 condition
Immunomodulatory agent
Tecfidera
71 trials
Indicated for 1 condition
CFTR modulator
Trikafta, Kaftrio
11 trials
Indicated for 1 condition
Bispecific monoclonal antibody
Hemlibra
12 trials
Indicated for 1 condition
S1PR modulators
Gilenya
69 trials
Indicated for 1 condition
Selective estrogen receptor degrader
Faslodex
85 trials
Indicated for 1 condition
Immunomodulatory agent
Copolymer 1
Copaxone
45 trials
Indicated for 1 condition
Enzyme replacement
Cerezyme
16 trials
Indicated for 1 condition
Anti-HER2 TKI
Tykerb, Tyverb
67 trials
Indicated for 1 condition
Bcr-Abl TKI
Tasigna
45 trials
Indicated for 1 condition
CDK 4/6 inhibitor
Ibrance
82 trials
Indicated for 1 condition
CDK 4/6 inhibitor
Kisqali
54 trials
Indicated for 1 condition
Glutamate modulator
Rilutek
85 trials
Indicated for 1 condition
Anti-HER2 antibody-drug conjugate
Kadcyla
40 trials
Indicated for 1 condition